| Sep 14 |
Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024
|
| Sep 6 |
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone
|
| Aug 29 |
Bicycle Therapeutics (NASDAQ:BCYC) shareholders have earned a 26% CAGR over the last five years
|
| Aug 20 |
Bicycle Therapeutics Is Looking Increasingly Attractive
|
| Aug 9 |
What Makes Bicycle Therapeutics (BCYC) a New Buy Stock
|
| Aug 9 |
Wall Street Analysts See an 88.94% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High?
|
| Aug 7 |
Bicycle Therapeutics cut at B. Riley ahead of data readouts
|
| Aug 6 |
Bicycle Therapeutics GAAP EPS of -$0.77 beats by $0.35, revenue of $9.36M beats by $3.08M
|
| Aug 6 |
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results
|
| Aug 1 |
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
